BRIEF-Arrowhead Pharmaceuticals submits New Drug Application To U.S. FDA

Reuters
18 Nov 2024
BRIEF-Arrowhead Pharmaceuticals submits New Drug Application To U.S. FDA

Nov 18 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O:

  • ARROWHEAD PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR PLOZASIRAN FOR THE TREATMENT OF FAMILIAL CHYLOMICRONEMIA SYNDROME

  • ARROWHEAD PHARMACEUTICALS INC - TO SUBMIT PLOZASIRAN APPLICATIONS TO OTHER REGULATORS IN 2025

  • ARROWHEAD PHARMACEUTICALS INC - PALISADE STUDY MET PRIMARY AND SECONDARY ENDPOINTS

Source text: ID:nBw2s6RhDa

Further company coverage: ARWR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10